Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MPS I (JOT102)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
Menu
Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MPS I (JOT102)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
Developing Therapies for Alzheimer’s Disease as well as Targeted Rare Diseases Through Our Platform Product,
JOT
ROL
™
Home
About
Team
JOT Founders and Leadership Team
>
Christer Rosén
Jacob Uittenbogaard
Dr. Claes Wahlestedt, MD, Ph.D.
Marshall Hayward, Ph.D.
Shaun P Brothers, Ph.D.
Natalie McNamee
Alison Silva
Advisors
>
Scientific Advisory Board
Business Advisors
Sports Ambassadors
JOT101 Project Advisors
JOTROL™
JOTROL™ Pre-Clinical Studies
Pipeline
Friedreich's Ataxia (JOT101)
MPS I (JOT102)
MELAS Syndrome (JOT107)
Alzheimer's Disease (JOT108)
Partners
News
Contact
Investors
